DE60041545D1 - Regulierung mittels atp binding cassette transporter proteins abc1 - Google Patents

Regulierung mittels atp binding cassette transporter proteins abc1

Info

Publication number
DE60041545D1
DE60041545D1 DE60041545T DE60041545T DE60041545D1 DE 60041545 D1 DE60041545 D1 DE 60041545D1 DE 60041545 T DE60041545 T DE 60041545T DE 60041545 T DE60041545 T DE 60041545T DE 60041545 D1 DE60041545 D1 DE 60041545D1
Authority
DE
Germany
Prior art keywords
abc1
regulation
atp binding
binding cassette
transporter proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60041545T
Other languages
English (en)
Inventor
Richard M Lawn
David Wade
Michael Garvin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Application granted granted Critical
Publication of DE60041545D1 publication Critical patent/DE60041545D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
DE60041545T 1999-06-18 2000-06-16 Regulierung mittels atp binding cassette transporter proteins abc1 Expired - Fee Related DE60041545D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19
PCT/US2000/016765 WO2000078972A2 (en) 1999-06-18 2000-06-16 Regulation with binding cassette transporter protein abc1

Publications (1)

Publication Number Publication Date
DE60041545D1 true DE60041545D1 (de) 2009-03-26

Family

ID=27385472

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041545T Expired - Fee Related DE60041545D1 (de) 1999-06-18 2000-06-16 Regulierung mittels atp binding cassette transporter proteins abc1

Country Status (19)

Country Link
EP (2) EP1218515B1 (de)
JP (4) JP2003508031A (de)
KR (2) KR20020012612A (de)
CN (2) CN1379817A (de)
AR (2) AR024576A1 (de)
AT (1) ATE422545T1 (de)
AU (3) AU5743400A (de)
BR (2) BR0011753A (de)
CA (2) CA2375781A1 (de)
DE (1) DE60041545D1 (de)
HK (2) HK1046427A1 (de)
IL (2) IL147021A0 (de)
MX (2) MXPA01013175A (de)
NO (2) NO20016114L (de)
NZ (3) NZ529785A (de)
SG (2) SG121853A1 (de)
TR (2) TR200200441T2 (de)
TW (2) TWI304737B (de)
WO (2) WO2000078971A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854880A1 (de) * 1999-03-15 2007-11-14 University of British Columbia Verfahren und Reagenzien zur Modulation von Cholesterinspiegeln
CA2367955C (en) 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
EP1239848A2 (de) * 1999-09-01 2002-09-18 University of British Columbia Zusammensetzungen und verfahren zur modulation des hdl-cholesterin- und triglyceridspiegels
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
BR0110541A (pt) 2000-05-02 2003-04-01 Aventis Pharma Sa ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato
EP1203588A1 (de) * 2000-11-06 2002-05-08 Bayer Ag Sterol-unabhängige Regulierung des ABC1 Promotors mit OncostatinM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2003004692A2 (en) * 2001-07-03 2003-01-16 Xenon Genetics, Inc. Screening processes for agents modulating cholesterol levels
WO2003033023A1 (fr) * 2001-10-12 2003-04-24 Grelan Pharmaceutical Co., Ltd. Medicaments ameliorant l'hypocholesterolemie hdl
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
ES2367539T3 (es) 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
US8466143B2 (en) 2003-07-23 2013-06-18 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP5227803B2 (ja) 2006-11-24 2013-07-03 ハイクス ラボラトリーズ合同会社 スピロキノン化合物及び医薬組成物
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
JP2011525476A (ja) 2008-03-05 2011-09-22 アブリンクス エン．ヴェー． 新規の抗原結合二量体複合体、その製造方法及び使用
CA2720763A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
EP2403873A1 (de) 2009-03-05 2012-01-11 Ablynx N.V. Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
US20120053229A1 (en) * 2009-03-31 2012-03-01 The General Hospital Corporation Regulation of MIR-33 MicroRNAs in the Treatment of Cholesterol-Related Disorders
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
SI2435410T1 (sl) 2009-05-28 2017-06-30 Bristol-Myers Squibb Company Lxr modulatorji
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
AR083784A1 (es) 2010-11-08 2013-03-20 Novartis Ag Polipeptidos de enlace de los receptores de quimiocina
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
EP2723772A1 (de) 2011-06-23 2014-04-30 Ablynx N.V. Gegen ige gerichtete variable immunglobulin-einzeldomänen
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
KR20150023729A (ko) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
JP6442475B2 (ja) 2013-03-15 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
TN2018000180A1 (en) 2015-11-27 2019-10-04 Ablynx Nv Polypeptides inhibiting cd40l
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
CA3064318A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
SG10202113337YA (en) 2017-06-02 2021-12-30 Ablynx Nv Aggrecan binding immunoglobulins
AU2018277343A1 (en) 2017-06-02 2020-01-02 Ablynx N.V. Adamts binding immunoglobulins
EP3630178A1 (de) 2017-06-02 2020-04-08 Merck Patent GmbH Mmp13-bindende immunglobuline
CN115433733A (zh) 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110541A (pt) * 2000-05-02 2003-04-01 Aventis Pharma Sa ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato

Also Published As

Publication number Publication date
TR200200441T2 (tr) 2002-11-21
BR0011696A (pt) 2002-04-30
WO2000078972A2 (en) 2000-12-28
HK1046708A1 (zh) 2003-01-24
NO20016114L (no) 2002-02-12
CN1379817A (zh) 2002-11-13
WO2000078972A8 (en) 2001-06-21
TWI259205B (en) 2006-08-01
EP1218515B1 (de) 2009-02-11
KR20020012281A (ko) 2002-02-15
AU2005200171A1 (en) 2005-02-10
NZ529785A (en) 2005-09-30
NO20016114D0 (no) 2001-12-14
TR200200440T2 (tr) 2002-09-23
CA2375781A1 (en) 2000-12-28
CN1434865A (zh) 2003-08-06
JP2005112859A (ja) 2005-04-28
HK1046427A1 (zh) 2003-01-10
EP1218515A2 (de) 2002-07-03
MXPA01013174A (es) 2002-06-04
NZ516061A (en) 2004-04-30
MXPA01013175A (es) 2002-06-04
CA2375787C (en) 2007-03-27
WO2000078972A3 (en) 2002-05-02
IL147022A0 (en) 2002-08-14
NO20016121D0 (no) 2001-12-14
JP4277956B2 (ja) 2009-06-10
CA2375787A1 (en) 2000-12-28
BR0011753A (pt) 2002-04-30
AU5746700A (en) 2001-01-09
JP2003506097A (ja) 2003-02-18
IL147021A0 (en) 2002-08-14
ATE422545T1 (de) 2009-02-15
JP2006137750A (ja) 2006-06-01
NO20016121L (no) 2002-02-12
JP2003508031A (ja) 2003-03-04
AU777461B2 (en) 2004-10-14
TW200626176A (en) 2006-08-01
WO2000078971A3 (en) 2002-01-17
EP1190065A2 (de) 2002-03-27
WO2000078971A2 (en) 2000-12-28
AR024576A1 (es) 2002-10-16
KR20020012612A (ko) 2002-02-16
SG121852A1 (en) 2006-05-26
AU5743400A (en) 2001-01-09
WO2000078972A9 (en) 2002-07-18
KR100476519B1 (ko) 2005-03-17
NZ531401A (en) 2005-08-26
AR024391A1 (es) 2002-10-02
CN100513570C (zh) 2009-07-15
TWI304737B (en) 2009-01-01
SG121853A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
DE60041545D1 (de) Regulierung mittels atp binding cassette transporter proteins abc1
DE60010448D1 (de) Amid-derivate
NO20022751D0 (no) Basisforbindelse med forbedret proteininnhold
DE50015735D1 (de) Magnetisches lagersystem
EG19893A (fr) Nouveaux phenylpyrazoles fongicides
DE60037521D1 (de) Magnetischer sensor
DE60036629D1 (de) Magnetischer sensor
DE60024522D1 (de) Luft-Kraftstoffverhältnis-Steuerungssystem
NO20022958D0 (no) Navigering
FR2802447B1 (fr) Systeme vaporisateur rechargeable
DE60037522D1 (de) Magnetischer sensor
DE10082436D2 (de) Wirbelsäulensegment
DE60004583D1 (de) Regler
DE19983986T1 (de) Servosteuersystem
NO20021275L (no) Transgentproduserte fusjonsproteiner
DE69710729T2 (de) Fungizide zusammensetzung mit erhörter bioverfügbarkeit
DE50004258D1 (de) Transportvorrichtung
ATE249427T1 (de) Diacylhydrazinderivate
DE50009424D1 (de) Magnetischer positionssensor
ID27293A (id) Rangkaian kendali pencahayaan lampu
ID24765A (id) Lampu fluoresen
ATE278712T1 (de) Antikörper gegen plazentaprotein 13
NO20013933D0 (no) Peptider
KR970026685U (ko) 방향설정이 가능한 장신용 악세사리
DE29909109U1 (de) Zusammengesetzter Aktenordner

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee